ArticleEuropean heart journal. Quality of care & clinical outcomes2025

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy.

Ingrid Engebretsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.